{"result": "(\"entity\"<|>DIABETES<|>EVENT<|>Diabetes is a chronic condition that affects how the body processes blood sugar (glucose). It is often associated with cardiovascular diseases and requires careful management of blood sugar levels.)\n##\n(\"entity\"<|>GLP-1<|>EVENT<|>GLP-1 (Glucagon-like peptide-1) is a hormone involved in the regulation of insulin secretion and glucose metabolism, playing a significant role in the management of diabetes.)\n##\n(\"entity\"<|>DPP-4<|>EVENT<|>Dipeptidyl peptidase-4 (DPP-4) is an enzyme that inactivates incretin hormones like GLP-1, affecting insulin secretion and glucose levels in the body.)\n##\n(\"entity\"<|>SITAGLIPTINA<|>ORGANIZATION<|>Sitagliptina is a medication used to treat type 2 diabetes by inhibiting the DPP-4 enzyme, thereby increasing levels of incretin hormones.)\n##\n(\"entity\"<|>LINAGLIPTINA<|>ORGANIZATION<|>Linagliptina is a DPP-4 inhibitor used in the management of type 2 diabetes, helping to control blood sugar levels.)\n##\n(\"entity\"<|>VILDAGLIPTINA<|>ORGANIZATION<|>Vildagliptina is another DPP-4 inhibitor that aids in the treatment of type 2 diabetes by enhancing insulin secretion.)\n##\n(\"entity\"<|>CLopidogrel<|>ORGANIZATION<|>Clopidogrel is a medication used as an antiplatelet agent, often prescribed for patients with cardiovascular diseases, especially those with a history of atherosclerosis.)\n##\n(\"relationship\"<|>SITAGLIPTINA<|>DPP-4<|>Sitagliptina works by inhibiting the DPP-4 enzyme, which is responsible for the inactivation of incretin hormones like GLP-1<|>8)\n##\n(\"relationship\"<|>LINAGLIPTINA<|>DPP-4<|>Linagliptina also inhibits DPP-4, thereby increasing the levels of GLP-1 and improving insulin secretion<|>8)\n##\n(\"relationship\"<|>VILDAGLIPTINA<|>DPP-4<|>Vildagliptina functions similarly by inhibiting DPP-4, which helps in managing blood sugar levels in diabetes<|>8)\n##\n(\"relationship\"<|>GLP-1<|>DPP-4<|>GLP-1 is inactivated by DPP-4, which affects its role in insulin secretion and glucose metabolism<|>9)\n##\n(\"relationship\"<|>CLopidogrel<|>DIABETES<|>Clopidogrel is used in patients with diabetes who have a history of cardiovascular diseases to prevent complications<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: a\n         D.  Todas las respuestas anteriores son falsas.                                                                                         reduce la producción de glucosa hepática y aumenta la utilización de glucosa periférica en\n                                                                                                                                                 casos de resistencia a la insulina.\n                                                                                                                                                 Tanto las sulfonilureas como las glinidas basan su mecanismo de acción en un aumento\n         COMENTARIO                                                                                                                              de la secreción       de insulina por las células β.            La secreción       de insulina está regulada por\n         Use la terapia con ácido acetilsalicílico (75-162 mg/día) como una estrategia de prevención                                             los canales de potasio dependientes de ATP, localizados en la membrana de la célula β.\n         secundaria en las personas con diabetes y un historial de enfermedad cardiovascular ate-                                                La unión de sulfonilureas y glinidas en distintos puntos a este canal de potasio (se une a\n         roesclerótica.                                                                                                                          un receptor propio denominado SUR-1) induce su cierre y una despolarización de la célula\n         Para pacientes con enfermedad cardiovascular ateroesclerótica y alergia documentada al                                                  β, que origina un incremento en la entrada de calcio en la célula y, como consecuencia, la\n                                                                                                                                                 liberación de insulina por exocitosis. La diferencia fundamental entre ambos grupos, sul-\n         ácido acetilsalicílico, se debe usar clopidogrel (75 mg/día).                                                                           fonilureas y glinidas, está en la duración corta de acción que presentan las glinidas, lo que\n         La terapia con ácido acetilsalicílico (75-162                  mg/día) se      puede considerar como una es-                            limita su acción hipoglucemiante a la comida en la cual se administró el fármaco. Además\n         trategia de prevención primaria en las personas con diabetes que tienen un mayor riesgo                                                 de este mecanismo de acción principal, se han descrito otros efectos extrapancreáticos,\n\n\n\n118                                                                                                                                                                                                                                                                            119\n---\n                                                                                                                                                                                                                             DIABETES                          2\n\n\n\n         como el aumento de la sensibilidad del tejido periférico a la insulina y la disminución de la                                 lo que su semivida apenas se prolonga en casos de ERC y por ello no precisa ajuste de dosis\n         sobreproducción de glucosa por parte del hígado.                                                                              ni siquiera en pacientes con ERC avanzada, incluida la diálisis.\n         GLP-1 y GIP son sustratos de la acción de una enzima proteolítica ampliamente distribuida,                                    Referencias:\n         tanto en forma de proteína soluble a nivel circulatorio como en numerosos tejidos, deno-                                      • Manual SEEN endocrinología. Disponible en: http://www.seen.es/manualSeen/manual.aspx (acceso 14 de marzo de 2019).\n         minada dipeptidil peptidasa 4 (DPP-4). La DPP-4 es responsable de la inactivación de estos\n         péptidos (vida media < 2 min).\n                                                                                                                                   61  ¿En cuál de los siguientes órganos no existen receptores de GLP-1?\n         Referencias:\n         • Manual SEEN endocrinología. Disponible en: http://www.seen.es/manualSeen/manual.aspx (acceso 14 de marzo de 2019).          A. Corazón.\n                                                                                                                                       B. Riñón.\n     60  No requieren ajuste de la dosis en casos de insuficiencia renal grave                                                         C. Estómago.\n         A. Sitagliptina.                                                                                                              D.  En todos existen.\n         B. Linagliptina.\n         C. Vildagliptina.                                                                                                             COMENTARIO\n         D.  Linagliptina y saxagliptina.                                                                                              De esta forma, el uso de cualquiera de estas tres moléculas en pacientes con ERC requerirá\n                                                                                                                                       un ajuste de dosis cuando el filtrado Se han identificado receptores de GLP-1 en diversos te-\n         COMENTARIO                                                                                                                    jidos además del páncreas, como: estómago, duodeno, tronco cerebral, tálamo, hipotálamo,\n                                                                                                                                       hipocampo, miocardio, pulmones, riñón, tejido muscular, adipocitos, músculo liso vascular,\n         Todas las moléculas comparten el mismo mecanismo de acción, si bien es cierto que pre-                                        células endoteliales, monocitos, macrófagos y hepatocitos. Sin embargo, las acciones de\n         sentan importantes diferencias farmacocinéticas que condicionan su forma de utilización                                       GLP-1 en ciertas localizaciones no están totalmente caracterizadas.\n         en presencia de enfermedad renal crónica (ERC). Sitagliptina, saxagliptina y vildagliptina se                                 El estómago tiene receptores de GIP y GLP-1. La estimulación de los receptores de GLP-\n         eliminan fundamentalmente por vía renal, bien sin metabolizar (sitagliptina) o como meta-                                     1 localizados en el esfínter pilórico causa un vaciamiento g\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}